Precision BioSciences, Inc. – NASDAQ:DTIL
Precision BioSciences stock price today
$4.8
+0.14
+3.23%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Precision BioSciences stock price monthly change
-54.10%
month
Precision BioSciences stock price quarterly change
-54.10%
quarter
Precision BioSciences stock price yearly change
+1187.73%
year
Precision BioSciences key metrics
Market Cap | 36.20M |
Enterprise value | N/A |
P/E | -0.62 |
EV/Sales | -2.92 |
EV/EBITDA | 0.72 |
Price/Sales | 3.55 |
Price/Book | 1.47 |
PEG ratio | N/A |
EPS | -7.58 |
Revenue | 57.53M |
EBITDA | -39.03M |
Income | -27.67M |
Revenue Q/Q | 100.27% |
Revenue Y/Y | 88.24% |
Profit margin | -444.8% |
Oper. margin | -399.9% |
Gross margin | 0% |
EBIT margin | -399.9% |
EBITDA margin | -67.85% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freePrecision BioSciences stock price history
Precision BioSciences stock forecast
Precision BioSciences financial statements
| Jun 2023 | 19.78M | -11.89M | -60.09% |
|---|---|---|---|
| Sep 2023 | 13.12M | -8.07M | -61.58% |
| Dec 2023 | 7.03M | -16.28M | -231.44% |
| Mar 2024 | 17.58M | 8.58M | 48.84% |
| Mar 2024 | 17.58M | 8.58M | 48.84% |
|---|---|---|---|
| Sep 2025 | 11M | -3.24M | -29.53% |
| Oct 2025 | 11M | -1.67M | -15.19% |
| Dec 2025 | 11M | -1.31M | -11.97% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 181697000 | 147.65M | 81.26% |
|---|---|---|---|
| Sep 2023 | 164344000 | 135.28M | 82.32% |
| Dec 2023 | 159781000 | 140.92M | 88.2% |
| Mar 2024 | 184741000 | 147.53M | 79.86% |
| Jun 2023 | -21.13M | -1.05M | 1.85M |
|---|---|---|---|
| Sep 2023 | -23.09M | 7.56M | -34K |
| Dec 2023 | -8.42M | 42K | 2.82M |
| Mar 2024 | -18.98M | -26K | 40.09M |
Precision BioSciences alternative data
| Aug 2023 | 197 |
|---|---|
| Sep 2023 | 192 |
| Oct 2023 | 192 |
| Nov 2023 | 192 |
| Dec 2023 | 115 |
| Jan 2024 | 115 |
| Feb 2024 | 115 |
| Mar 2024 | 115 |
| Apr 2024 | 115 |
| May 2024 | 109 |
| Jun 2024 | 109 |
| Jul 2024 | 109 |
Precision BioSciences other data
20.09%
-26.19%
of DTIL is owned by hedge funds
54
-44
17.65M
-33.64M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 0 | 208203 |
| Apr 2024 | 0 | 238 |
| May 2024 | 0 | 3160 |
| Jun 2024 | 0 | 143 |
| Nov 2024 | 3000 | 3600 |
| Dec 2024 | 3016 | 0 |
| Patent |
|---|
Application Filling date: 20 Aug 2020 Issue date: 1 Sep 2022 |
Application Filling date: 24 Jul 2020 Issue date: 1 Sep 2022 |
Application Filling date: 4 Feb 2022 Issue date: 4 Aug 2022 |
Application NUCLEIC ACID MOLECULES ENCODING AN ENGINEERED ANTIGEN RECEPTOR AND AN INHIBITORY NUCLEIC ACID MOLECULE AND METHODS OF USE THEREOF Filling date: 4 Apr 2022 Issue date: 21 Jul 2022 |
Grant Filling date: 26 Oct 2021 Issue date: 12 Jul 2022 |
Application Filling date: 3 Apr 2020 Issue date: 30 Jun 2022 |
Application Filling date: 10 Mar 2022 Issue date: 23 Jun 2022 |
Application Filling date: 7 May 2020 Issue date: 23 Jun 2022 |
Application NUCLEIC ACIDS ENCODING ENGINEERED MEGANUCLEASES WITH RECOGNITION SEQUENCES FOUND IN THE HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE Filling date: 31 Jan 2022 Issue date: 19 May 2022 |
Application Filling date: 26 Jan 2022 Issue date: 12 May 2022 |
| Insider | Compensation |
|---|---|
| Mr. Matthew R. Kane (1977) Advisor | $733,530 |
| Dr. Christopher R. Heery (1980) Consultant | $587,380 |
CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts
TG Therapeutics Made A Strong Impression At The J.P. Morgan Healthcare Conference
Precision Biosciences: Plenty Of Positive Updates; Waiting For The Market To Notice
Precision BioSciences: A Watch List Stock Going Into ASH Presentation
Precision BioSciences: CAR T Data Updates End Of 2022 And Plenty Of Cash
Precision Bio: Another CAR-T Laggard With No Solid Prospects
SpringWorks Is A Biotech To Watch With Several Partnerships And Solid Drug Pipeline
Precision BioSciences: Uniquely Positioned
MaxCyte: Enabling Next-Generation Cell Based Therapies, Attractive Risk-Return Profile
-
What's the price of Precision BioSciences stock today?
One share of Precision BioSciences stock can currently be purchased for approximately $4.8.
-
When is Precision BioSciences's next earnings date?
Unfortunately, Precision BioSciences's (DTIL) next earnings date is currently unknown.
-
Does Precision BioSciences pay dividends?
No, Precision BioSciences does not pay dividends.
-
How much money does Precision BioSciences make?
Precision BioSciences has a market capitalization of 36.20M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 94.15% to 48.73M US dollars.
-
What is Precision BioSciences's stock symbol?
Precision BioSciences, Inc. is traded on the NASDAQ under the ticker symbol "DTIL".
-
What is Precision BioSciences's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Precision BioSciences?
Shares of Precision BioSciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Precision BioSciences's key executives?
Precision BioSciences's management team includes the following people:
- Mr. Matthew R. Kane Advisor(age: 48, pay: $733,530)
- Dr. Christopher R. Heery Consultant(age: 45, pay: $587,380)
-
How many employees does Precision BioSciences have?
As Jul 2024, Precision BioSciences employs 109 workers, which is 5% less then previous quarter.
-
When Precision BioSciences went public?
Precision BioSciences, Inc. is publicly traded company for more then 6 years since IPO on 28 Mar 2019.
-
What is Precision BioSciences's official website?
The official website for Precision BioSciences is precisionbiosciences.com.
-
Where are Precision BioSciences's headquarters?
Precision BioSciences is headquartered at 302 East Pettigrew Street, Durham, NC.
-
How can i contact Precision BioSciences?
Precision BioSciences's mailing address is 302 East Pettigrew Street, Durham, NC and company can be reached via phone at +91 93145512.
Precision BioSciences company profile:
Precision BioSciences, Inc.
precisionbiosciences.comExchange:
NASDAQ
Full time employees:
108
Industry:
Biotechnology
Sector:
Healthcare
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
302 East Pettigrew Street
Durham, NC 27701
Durham, NC 27701
CIK: 0001357874
ISIN: US74019P2074
CUSIP: 74019P108
